VivoSeq
Oncology

Glioblastoma (GBM)

3

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Glioblastoma (GBM) is an early-stage landscape with 3 programs across 3 companies. The most active players are Diakonos Oncology Corporation, Black Diamond Therapeutics, Inc., Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Diakonos Oncology Corporation

2 programs

Phase 2B

Black Diamond Therapeutics, Inc.

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII
Recruiting·BBlack Diamond Therapeutics, Inc.·Phase 2·NCT07326566·162 enrolled
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma
Recruiting·DDiakonos Oncology Corporation·Phase 2·NCT06805305·180 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)